LSN862

peroxisome proliferator-activated receptor (PPAR)alpha/gamma dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia; structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Du, Eric: 1 article (01/2013)
2.	Emborg, Marina E: 1 article (01/2013)
3.	Johnson, Delinda A: 1 article (01/2013)
4.	Johnson, Jeffrey A: 1 article (01/2013)
5.	Swanson, Christine R: 1 article (01/2013)
6.	Barr, Robert: 1 article (06/2005)
7.	Bensch, William R: 1 article (06/2005)
8.	Brozinick, Joseph T: 1 article (06/2005)
9.	Bull, Chris: 1 article (06/2005)
10.	Dana, Sharon: 1 article (06/2005)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2013 - "In this study, we examined if LSN862 (LSN), a novel non-thiazoledinedione partial PPAR- γ agonist, was neuroprotective in a mouse model of Parkinson's disease (PD) and assessed possible mechanisms of action. "
2.	Dyslipidemias (Dyslipidemia) 06/01/2005 - "LSN862 is a novel peroxisome proliferator-activated receptor (PPAR)alpha/gamma dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. "
3.	Type 2 Diabetes Mellitus (MODY) 06/01/2005 - "In addition, LSN862 was examined in a second rodent model of type 2 diabetes, db/db mice. " 06/01/2005 - "LSN862 is a novel peroxisome proliferator-activated receptor (PPAR)alpha/gamma dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. "

Related Drugs and Biologics

1.	Peroxisome Proliferator-Activated Receptors (PPAR)
2.	leustroducsin A
3.	PPAR alpha
4.	Lipids
5.	Glucose (Dextrose)